Fenwick Represents Recludix Pharma in Strategic Collaboration with Sanofi

Fenwick represented Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, in its strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.

Under the terms of the agreement, Recludix will receive $125 million in near-term payments, and additionally, Recludix may receive more than $1.2 billion in potential development, regulatory and sales milestones, as well as up to double-digit royalties on possible future product sales. More information about the collaboration can be obtained from the announcement.

The Fenwick transaction team was led by life sciences partner Stefano Quintini and included partner Jake Handy and associate Leanne Ta.


Don’t have an account yet?